The Digital Future of Tuberculosis Elimination World Tuberculosis Day had been decades concerned with awareness. Today in 2026, it is no longer called surviving, but rather systematic elimination. As the global therapeutics market is expected to reach USD 2.51 billion in the current year, we are no longer only in a battle a gainst a disease; we are in the midst of a high - tech global health revolution. Innovation at a Glance: • The Diagnostic Churn is Over: Point - of - Care (PoC) Mdx is replacing conventional testing. According to our recent surveys, moving to PoC will help to decrease patient churn by 35 percent, which means treatment will commence the same day as diagnosis. • AI vs. The Human Eye: Computer - Aided Detection (CAD) is now powered by AI and has an accuracy score of 0.99, which has continuously surpassed radiologists in identifying lesions at their early stage of development. • The 6 - Month Revolution: The days of the 9 - month treatments have ended. Advanced drug markets are being fuelled by a 12.92% CAGR as the emergence of BPaL/BPaLM regimens is reducing drug - resistant TB treatment to only six months. • The Funding Cliff: With 100+ diagnostic products in the pipeline, high - risk, high - reward infectious disease research is threatened by the immediate dire financial position of the WHO. Asia - Pacific now dominates 47 percent of the world drug market, and it can only be as innovative as the data it runs on. What can the market leaders do to move through this Insight - to - Action framework so that promises really become cures? Read the full deep dive on the Digital Future of TB Tuberculosis here